Table 2 Reported metabolic outcomes and complications.
Authors | Participants (n) | Remission/improvement in type 2 diabetes mellitusa (%) | Remission/improvement in hypertension (%) | Remission/improvement in dyslipidaemia (%) | Complication Incidence (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Short Limb | Long Limb | Short Limb | Long Limb | Short Limb | Long Limb | Short Limb | Long Limb | Short Limb | Long Limb | |
Brolin et al. | 22 | 23 | NR | NR | NR | NR | NR | NR | NR | NR |
Inabnet et al. | 25 | 23 | NR | NR | NR | NR | NR | NR | 13/25 (52.0%) | 13/23 (56.5%) |
Pinheiro et al. | 57 | 48 | 54/55 (98.2%) | 43/45 (95.6%) | 13/26 (50.0%) | 13/21 (63.0%) | 30/52 (57.7%) | 29/41 (70.7%) | NR | NR |
Nergaard et al. | 93 | 94 | 12/17 (70.6%) | 17/22 (77.3%) | 22/31 (71.0%) | 17/28 (60.7%) | NR | NR | NR | NR |
Valezi et al. | 49 | 45 | NR | NR | NR | NR | NR | NR | NR | NR |
Homan et al. | 74 | 72 | 21/22 (95.5%) | 22/22 (100.0%) | 19/24 (79.2%) | 26/33 (78.8%) | 50/60 (83.3%) | 53/58 (91.4%) | 29/74 (39.2%) | 27/72 (37.5%) |
Boerboom et al. | 72 | 72 | 11/15 (73.3%) | 6/9 (66.7%) | 9/18 (50.0%) | 10/24 (37.5%) | 8/13 (61.5%) | 4/7 (57.1%) | 28/72 (38.9%) | 29/72 (40.3%) |
Ruiz Tovar et al. | 253 | 253 | 30/90 (33.3%) | 30/85 (35.3%) | 40/120 (33.3%) | 42/112 (37.5%) | 39/82 (47.6%) | 41/80 (51.2%) | NR | NR |
Miras et al. | 27 | 26 | 16/26 (61.5%) | 20/26 (76.9%) | NR | NR | NR | NR | 18/27 (66.7%) | 23/26 (88.5%) |
Nergård et al. | 74 | 66 | 13/15 (86.7%) | 15/15 (100.0%) | 12/23 (52.2%) | 14/19 (73.7%) | NR | NR | 7/74 (9.46%) | 12/66 (18.2%) |
Overallb | 746 | 722 | 73.3% | 77.3% | 51.1% | 60.7% | 59.6% | 63.9% | 39.2% | 40.3% |
